* William Rutter, chairman at Chiron Corp., ofEmeryville, Calif., received a 1995 Heinz Award in thecategory of "Technology and the Economy." The awardwas created by philanthropist Teresa Heinz to celebratethe power of the individual in America.

* Endogen Inc., of Cambridge, Mass., expanded itssupply and marketing agreement with AmershamInternational plc, of Buckinghamshire, England, toinclude human cytokine test kits. Last year the companiesentered a worldwide supply and marketing agreementrelated to Endogen's mouse cytokine ELISA kits.

* Genelabs Technologies Inc., of Redwood City, Calif.,said enrollment was completed in its Phase III trial ofGL701 for systemic lupus erythematosus. The 192-patientplacebo-controlled study was started in May 1994.

* Hoffmann-La Roche Inc., of Nutley, N.J., said the FDAcleared for marketing Vesanoid (all-trans retinoic acid)for the treatment of acute promyelocytic leukemia. It isthe first retinoid or vitamin A derivative to be indicatedfor cancer in the U.S.

* Immunex Corp., of Seattle, is presenting papers at theAmerican Society of Hematology conference, in Seattle,that showed its Flt3 ligand promoted in mice the growthof dendritic cells, which play a role in initiating immuneresponses.

* Neurogen Corp., of Branford, Conn., completed itsagreement with Pfizer Inc., of New York, fordevelopment of drugs for obesity and eating disorders.Neurogen received a $16.5 million equity investment anda $3.5 million licensing fee in the potential $60 milliondeal. (See BioWorld Today, Nov. 7, 1995, p. 1.)

* Stockholders of North American Biologicals Inc., aplasma supplier, and Univax Biologics Inc., a developerof plasma-derived antibody-based drugs, Wednesdayapproved a merger of the two firms. The new company'ssales, marketing and administrative divisions will beconsolidated in Boca Raton, Fla. and research anddevelopment facilities will be in Rockville, Md. Thecompany, which will retain the name North AmericanBiologicals Inc., plans to start six new clinical trials in1996.

* Organogenesis Inc., of Canton, Mass., received noticethat its Graftskin premarket approval application issuitable for filing.

* Rhone-Poulenc Rorer Inc., of Paris, said the EuropeanCommission granted marketing authorization forTaxotere for the treatment of locally advanced ormetastatic breast cancer that is resistant to or has recurredafter chemotherapy. The approval is valid in the EuropeanUnion's 15 member countries.

* Somatix Therapy Corp., of Alameda, Calif., obtained aworldwide exclusive license from Rockefeller University,of New York, and two scientists for a method ofdelivering genes to heart muscle using adeno-associatedviral vectors.

* Xenova Group plc, of Slough, U.K., extended to mid-1997 its drug discovery collaboration with Suntory Ltd.,of Osaka, Japan. The companies have collaborated sinceApril 1993 on small molecule drugs to treat immune-inflammatory diseases, primarily rheumatoid arthritis.Terms of the extension were not disclosed.

* Yamanouchi Pharmaceutical Co. Ltd., of Tokyo, andProtein Design Labs Inc., of Mountain View, Calif.,reported in an abstract at the American Society ofHematology meeting in Seattle that a humanized antibodyfragment completely inhibited platelet aggregation withlittle effect on bleeding in a study in rhesus monkeys.

(c) 1997 American Health Consultants. All rights reserved.